Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Jehanne

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pediatric Blood & Cancer|May 30, 2009
Monitoring of ototoxicity in young children receiving carboplatin for retinoblastomaMathilde Jehanne, Ghislaine Mercier, François Doz
La Revue Du Praticien|September 29, 2007
[Retinoblastoma: systematic removal in cases of white pupillary reflection or strabismus]Mathilde Jehanne, Livia Lumbroso, Isabelle Aerts, et al.
Bulletin Du Cancer|May 6, 2014
[Retinoblastoma: recent advances]Mathilde Jehanne, Hervé Brisse, Marion Gauthier-Villars, et al.
JAMA Oncology|July 17, 2015
Vemurafenib Use in an Infant for High-Risk Langerhans Cell HistiocytosisSébastien Héritier, Mathilde Jehanne, Guy Leverger, et al.
Pediatric Blood & Cancer|January 17, 2009
Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastomaMathilde Jehanne, Livia Lumbroso-Le Rouic, Alexia Savignoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2019
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational StudyJean Donadieu, Islam Amine Larabi, Mathilde Tardieu, et al.
Hemasphere|May 11, 2026
Splenectomy in β-thalassemia patients: Practices and risks in a nationwide studyAudrey Benoit, Justine Pages, Sarah Szepetowski, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pediatric Blood & Cancer|May 30, 2009
Monitoring of ototoxicity in young children receiving carboplatin for retinoblastomaMathilde Jehanne, Ghislaine Mercier, François Doz
La Revue Du Praticien|September 29, 2007
[Retinoblastoma: systematic removal in cases of white pupillary reflection or strabismus]Mathilde Jehanne, Livia Lumbroso, Isabelle Aerts, et al.
Bulletin Du Cancer|May 6, 2014
[Retinoblastoma: recent advances]Mathilde Jehanne, Hervé Brisse, Marion Gauthier-Villars, et al.
JAMA Oncology|July 17, 2015
Vemurafenib Use in an Infant for High-Risk Langerhans Cell HistiocytosisSébastien Héritier, Mathilde Jehanne, Guy Leverger, et al.
Pediatric Blood & Cancer|January 17, 2009
Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastomaMathilde Jehanne, Livia Lumbroso-Le Rouic, Alexia Savignoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2019
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational StudyJean Donadieu, Islam Amine Larabi, Mathilde Tardieu, et al.
Hemasphere|May 11, 2026
Splenectomy in β-thalassemia patients: Practices and risks in a nationwide studyAudrey Benoit, Justine Pages, Sarah Szepetowski, et al.
Pageof 1